Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship

Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the pre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2016-02, Vol.69 (2), p.276-283
Hauptverfasser: Cai, Tommaso, Verze, Paolo, Brugnolli, Anna, Tiscione, Daniele, Luciani, Lorenzo Giuseppe, Eccher, Cristina, Lanzafame, Paolo, Malossini, Gianni, Wagenlehner, Florian M.E, Mirone, Vincenzo, Bjerklund Johansen, Truls E, Pickard, Robert, Bartoletti, Riccardo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 283
container_issue 2
container_start_page 276
container_title European urology
container_volume 69
creator Cai, Tommaso
Verze, Paolo
Brugnolli, Anna
Tiscione, Daniele
Luciani, Lorenzo Giuseppe
Eccher, Cristina
Lanzafame, Paolo
Malossini, Gianni
Wagenlehner, Florian M.E
Mirone, Vincenzo
Bjerklund Johansen, Truls E
Pickard, Robert
Bartoletti, Riccardo
description Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p < 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p < 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidel
doi_str_mv 10.1016/j.eururo.2015.05.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760875898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0302283815004121</els_id><sourcerecordid>1760875898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EotvCP0DIRy5Zxsna8XJAWlWlrVQJpNKz5dhj1ksSB9sB7Zk_jsMWDlyQRvLXM-_Yr4eQVwzWDJh4e1jjHOcY1jUwvoYSDJ6QFZNtU7VcwFOyggbqqpaNPCPnKR0AoOHb5jk5qwUUCQYr8nNn9xhxNEhzoFdFb0I90l1KwXidfRhpcPQhhj58OdLr2Vvs_YiJloNPBd4fe22yN3Q3Zt_5UKbpXVnQ22EKMesx0_uME_Xjb2LwJobO637Z_aGjTXs_vSDPnO4TvnwcL8jDh6vPlzfV3cfr28vdXWU4E7kSHFzn6nrrNNN2w7Vs6m2nhW4t74RxrO1k6_jG2QJJLgQz3FjZdk6jEa1pLsibk-4Uw7cZU1aDTwb7Xo8Y5qRYK0C2XG5lQTcntFw3pYhOTdEPOh4VA7XYrw7qZL9a7FdQgkFJe_1YYe4GtH-T_vhdgPcnAMs7v3uMKhm_uG99RJOVDf5_Ff4VMOU_vNH9VzxiOoQ5jsVDxVSqFaj7pQWWDmAcYMNq1vwCKVSwRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760875898</pqid></control><display><type>article</type><title>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cai, Tommaso ; Verze, Paolo ; Brugnolli, Anna ; Tiscione, Daniele ; Luciani, Lorenzo Giuseppe ; Eccher, Cristina ; Lanzafame, Paolo ; Malossini, Gianni ; Wagenlehner, Florian M.E ; Mirone, Vincenzo ; Bjerklund Johansen, Truls E ; Pickard, Robert ; Bartoletti, Riccardo</creator><creatorcontrib>Cai, Tommaso ; Verze, Paolo ; Brugnolli, Anna ; Tiscione, Daniele ; Luciani, Lorenzo Giuseppe ; Eccher, Cristina ; Lanzafame, Paolo ; Malossini, Gianni ; Wagenlehner, Florian M.E ; Mirone, Vincenzo ; Bjerklund Johansen, Truls E ; Pickard, Robert ; Bartoletti, Riccardo</creatorcontrib><description>Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p &lt; 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p &lt; 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidelines reduced the rate of bacterial resistance, in particular against piperacillin/tazobactam, gentamicin, and ciprofloxacin, and reduced costs without increasing the risk of postoperative infection after urologic procedures. We recommend adherence to the guidelines as an important part of antibiotic stewardship programmes.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2015.05.010</identifier><identifier>PMID: 26001610</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - economics ; Anti-Bacterial Agents - therapeutic use ; Antibiotic Prophylaxis - standards ; Antimicrobial prophylaxis ; Ciprofloxacin - therapeutic use ; Cost saving ; Drug Resistance, Bacterial ; Escherichia coli - drug effects ; Europe ; Female ; Gentamicins - therapeutic use ; Guideline Adherence ; Guidelines ; Humans ; Klebsiella - drug effects ; Male ; Middle Aged ; Penicillanic Acid - analogs &amp; derivatives ; Penicillanic Acid - therapeutic use ; Piperacillin - therapeutic use ; Piperacillin, Tazobactam Drug Combination ; Practice Guidelines as Topic ; Surgical urology ; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use ; Urinary tract infection ; Urologic Surgical Procedures - adverse effects ; Urologic Surgical Procedures - standards ; Urology ; Urology - standards</subject><ispartof>European urology, 2016-02, Vol.69 (2), p.276-283</ispartof><rights>European Association of Urology</rights><rights>2015 European Association of Urology</rights><rights>Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</citedby><cites>FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283815004121$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26001610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Tommaso</creatorcontrib><creatorcontrib>Verze, Paolo</creatorcontrib><creatorcontrib>Brugnolli, Anna</creatorcontrib><creatorcontrib>Tiscione, Daniele</creatorcontrib><creatorcontrib>Luciani, Lorenzo Giuseppe</creatorcontrib><creatorcontrib>Eccher, Cristina</creatorcontrib><creatorcontrib>Lanzafame, Paolo</creatorcontrib><creatorcontrib>Malossini, Gianni</creatorcontrib><creatorcontrib>Wagenlehner, Florian M.E</creatorcontrib><creatorcontrib>Mirone, Vincenzo</creatorcontrib><creatorcontrib>Bjerklund Johansen, Truls E</creatorcontrib><creatorcontrib>Pickard, Robert</creatorcontrib><creatorcontrib>Bartoletti, Riccardo</creatorcontrib><title>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p &lt; 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p &lt; 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidelines reduced the rate of bacterial resistance, in particular against piperacillin/tazobactam, gentamicin, and ciprofloxacin, and reduced costs without increasing the risk of postoperative infection after urologic procedures. We recommend adherence to the guidelines as an important part of antibiotic stewardship programmes.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - economics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic Prophylaxis - standards</subject><subject>Antimicrobial prophylaxis</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Cost saving</subject><subject>Drug Resistance, Bacterial</subject><subject>Escherichia coli - drug effects</subject><subject>Europe</subject><subject>Female</subject><subject>Gentamicins - therapeutic use</subject><subject>Guideline Adherence</subject><subject>Guidelines</subject><subject>Humans</subject><subject>Klebsiella - drug effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Penicillanic Acid - analogs &amp; derivatives</subject><subject>Penicillanic Acid - therapeutic use</subject><subject>Piperacillin - therapeutic use</subject><subject>Piperacillin, Tazobactam Drug Combination</subject><subject>Practice Guidelines as Topic</subject><subject>Surgical urology</subject><subject>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><subject>Urinary tract infection</subject><subject>Urologic Surgical Procedures - adverse effects</subject><subject>Urologic Surgical Procedures - standards</subject><subject>Urology</subject><subject>Urology - standards</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk1v1DAQhi0EotvCP0DIRy5Zxsna8XJAWlWlrVQJpNKz5dhj1ksSB9sB7Zk_jsMWDlyQRvLXM-_Yr4eQVwzWDJh4e1jjHOcY1jUwvoYSDJ6QFZNtU7VcwFOyggbqqpaNPCPnKR0AoOHb5jk5qwUUCQYr8nNn9xhxNEhzoFdFb0I90l1KwXidfRhpcPQhhj58OdLr2Vvs_YiJloNPBd4fe22yN3Q3Zt_5UKbpXVnQ22EKMesx0_uME_Xjb2LwJobO637Z_aGjTXs_vSDPnO4TvnwcL8jDh6vPlzfV3cfr28vdXWU4E7kSHFzn6nrrNNN2w7Vs6m2nhW4t74RxrO1k6_jG2QJJLgQz3FjZdk6jEa1pLsibk-4Uw7cZU1aDTwb7Xo8Y5qRYK0C2XG5lQTcntFw3pYhOTdEPOh4VA7XYrw7qZL9a7FdQgkFJe_1YYe4GtH-T_vhdgPcnAMs7v3uMKhm_uG99RJOVDf5_Ff4VMOU_vNH9VzxiOoQ5jsVDxVSqFaj7pQWWDmAcYMNq1vwCKVSwRw</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Cai, Tommaso</creator><creator>Verze, Paolo</creator><creator>Brugnolli, Anna</creator><creator>Tiscione, Daniele</creator><creator>Luciani, Lorenzo Giuseppe</creator><creator>Eccher, Cristina</creator><creator>Lanzafame, Paolo</creator><creator>Malossini, Gianni</creator><creator>Wagenlehner, Florian M.E</creator><creator>Mirone, Vincenzo</creator><creator>Bjerklund Johansen, Truls E</creator><creator>Pickard, Robert</creator><creator>Bartoletti, Riccardo</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</title><author>Cai, Tommaso ; Verze, Paolo ; Brugnolli, Anna ; Tiscione, Daniele ; Luciani, Lorenzo Giuseppe ; Eccher, Cristina ; Lanzafame, Paolo ; Malossini, Gianni ; Wagenlehner, Florian M.E ; Mirone, Vincenzo ; Bjerklund Johansen, Truls E ; Pickard, Robert ; Bartoletti, Riccardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - economics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic Prophylaxis - standards</topic><topic>Antimicrobial prophylaxis</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Cost saving</topic><topic>Drug Resistance, Bacterial</topic><topic>Escherichia coli - drug effects</topic><topic>Europe</topic><topic>Female</topic><topic>Gentamicins - therapeutic use</topic><topic>Guideline Adherence</topic><topic>Guidelines</topic><topic>Humans</topic><topic>Klebsiella - drug effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Penicillanic Acid - analogs &amp; derivatives</topic><topic>Penicillanic Acid - therapeutic use</topic><topic>Piperacillin - therapeutic use</topic><topic>Piperacillin, Tazobactam Drug Combination</topic><topic>Practice Guidelines as Topic</topic><topic>Surgical urology</topic><topic>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</topic><topic>Urinary tract infection</topic><topic>Urologic Surgical Procedures - adverse effects</topic><topic>Urologic Surgical Procedures - standards</topic><topic>Urology</topic><topic>Urology - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cai, Tommaso</creatorcontrib><creatorcontrib>Verze, Paolo</creatorcontrib><creatorcontrib>Brugnolli, Anna</creatorcontrib><creatorcontrib>Tiscione, Daniele</creatorcontrib><creatorcontrib>Luciani, Lorenzo Giuseppe</creatorcontrib><creatorcontrib>Eccher, Cristina</creatorcontrib><creatorcontrib>Lanzafame, Paolo</creatorcontrib><creatorcontrib>Malossini, Gianni</creatorcontrib><creatorcontrib>Wagenlehner, Florian M.E</creatorcontrib><creatorcontrib>Mirone, Vincenzo</creatorcontrib><creatorcontrib>Bjerklund Johansen, Truls E</creatorcontrib><creatorcontrib>Pickard, Robert</creatorcontrib><creatorcontrib>Bartoletti, Riccardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Tommaso</au><au>Verze, Paolo</au><au>Brugnolli, Anna</au><au>Tiscione, Daniele</au><au>Luciani, Lorenzo Giuseppe</au><au>Eccher, Cristina</au><au>Lanzafame, Paolo</au><au>Malossini, Gianni</au><au>Wagenlehner, Florian M.E</au><au>Mirone, Vincenzo</au><au>Bjerklund Johansen, Truls E</au><au>Pickard, Robert</au><au>Bartoletti, Riccardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>69</volume><issue>2</issue><spage>276</spage><epage>283</epage><pages>276-283</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p &lt; 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p &lt; 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidelines reduced the rate of bacterial resistance, in particular against piperacillin/tazobactam, gentamicin, and ciprofloxacin, and reduced costs without increasing the risk of postoperative infection after urologic procedures. We recommend adherence to the guidelines as an important part of antibiotic stewardship programmes.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>26001610</pmid><doi>10.1016/j.eururo.2015.05.010</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2016-02, Vol.69 (2), p.276-283
issn 0302-2838
1873-7560
language eng
recordid cdi_proquest_miscellaneous_1760875898
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Aged, 80 and over
Anti-Bacterial Agents - economics
Anti-Bacterial Agents - therapeutic use
Antibiotic Prophylaxis - standards
Antimicrobial prophylaxis
Ciprofloxacin - therapeutic use
Cost saving
Drug Resistance, Bacterial
Escherichia coli - drug effects
Europe
Female
Gentamicins - therapeutic use
Guideline Adherence
Guidelines
Humans
Klebsiella - drug effects
Male
Middle Aged
Penicillanic Acid - analogs & derivatives
Penicillanic Acid - therapeutic use
Piperacillin - therapeutic use
Piperacillin, Tazobactam Drug Combination
Practice Guidelines as Topic
Surgical urology
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
Urinary tract infection
Urologic Surgical Procedures - adverse effects
Urologic Surgical Procedures - standards
Urology
Urology - standards
title Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A27%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20European%20Association%20of%20Urology%20Guidelines%20on%20Prophylactic%20Antibiotics:%20An%20Important%20Step%20in%20Antimicrobial%20Stewardship&rft.jtitle=European%20urology&rft.au=Cai,%20Tommaso&rft.date=2016-02-01&rft.volume=69&rft.issue=2&rft.spage=276&rft.epage=283&rft.pages=276-283&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2015.05.010&rft_dat=%3Cproquest_cross%3E1760875898%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760875898&rft_id=info:pmid/26001610&rft_els_id=1_s2_0_S0302283815004121&rfr_iscdi=true